AbbVie hands Voyager a mega-billions gene therapy deal, with $310M in near-term cash
Gene therapy company Voyager Therapeutics has kicked off 2019 in style. After forging an up to $1.8 billion pact with Neurocrine last month, the Parkinson’s drug developer expanded its partnership with AbbVie on Friday, days following the anniversary of their original pact.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.